АЛЬБУМИНУРИЯ - МАРКЕР ПОРАЖЕНИЯ ПОЧЕК И РИСКА СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ
- Авторы: Мухин НА1, Арутюнов ГП2, Фомин ВВ1, Mukhin NA3, Arutyunov GP3, Fomin VV3
-
Учреждения:
- ММА имени И.М. Сеченова
- РГМУ
- Выпуск: № 1 (2009)
- Страницы: 5-10
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2075-3594/article/view/245795
- ID: 245795
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
Н А Мухин
ММА имени И.М. СеченоваММА имени И.М. Сеченова
Г П Арутюнов
РГМУРГМУ
В В Фомин
ММА имени И.М. СеченоваММА имени И.М. Сеченова
N A Mukhin
G P Arutyunov
V V Fomin
Список литературы
- Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50 - 55.
- De Jong P.E., Brenner B.M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004; 66: 2109-2118.
- ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21: 1011- 053.
- Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
- The ESH-ESC Task Force. 2007 Guidelines for the Management of the Arterial Hypertension. J. Hypertens. 2007; 25: 1105-1187.
- Schmieder R.E., Schrader J., Zidek W. et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin. Res. Cardiol. 2007; 96(5): 247-257.
- Arnlöv J., Evans J.C., Meigs J.B. et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005; 112(7): 969-975.
- Lieb W., Mayer B., Stritzke J. et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol. Dial. Transplant. 2006; 21(10): 2780-2787.
- Sung K.C., Kim B.J., Ryu S. An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. Atherosclerosis. 2008; 196(1): 320-326.
- Wang T.J., Evans J.C., Meigs J.B. et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005; 111(11): 1370-1376.
- Ochodnicky P., Henning R.H., van Dokkum R.P., de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc. Pharmacol. 2006; 47 (Suppl. 2): S151-S162.
- Tsakiris A., Doumas M., Lagatouras D. et al. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology. 2006; 57 (3): 313-320.
- Metclaf P., Baker J., Scott A. et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension and hyperlipidemia. Clin. Chem. 1992; 38: 1802-1808.
- Redon J., Miralles A., Pascual J.M. et al. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J. Hypertens. 1997;.15 (1): 79-86.
- Shankar S.S., Steinberg H.O. Obesity and endothelial dysfunction. Semin. Vasc. Med. 2005; 5: 56-64.
- Сагинова Е.А., Федорова Е.А., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. арх. 2005; 5: 36-41.
- Lekatsas I., Koulouris S., Triantafyllou K. et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction. Int. J. Cardiol. 2006; 106 (2): 218-223.
- Szczudlik A., Turaj W., Slowik A., Strojny J. Microalbuminuria and hyperthermia independently predict long-term.mortality in acute ischemic stroke patients. Acta Neurol. Scand. 2003; 107: 96-101.
- Terao Y., Miura K., Ichinomiya T. et al. Admission microalbuminuria and neurologic outcomes in intensive care unit.patients with spontaneous intracerebral hemorrhage. J. Neurosurg. Anesthesiol. 2008; 20(3): 163-168.
- Barzilay J.I., Fitzpatrick A.L., Luchsinger J. et al. Albuminuria and dementia in the elderly: a community study. Am. J. Kidney Dis. 2008; 52(2): 216-226.
- Wachtell K., Palmieri V., Olsen M.H. et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am. Heart J. 2002; 143(2): 319-326.
- Torun D., Sezer S., Arat Z. et al. The frequency of combined target organ damage and the beneficial effect of ambulatory blood pressure monitoring in never treated mild-to-moderate hypertensive patients. Int. Heart J. 2005; 46 (6): 1073-1082.
- Munakata M., Nunokawa T., Yoshinaga K. et al. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension - a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens. Res. 2006; 29(7): 515-521.
- Dalla Vestra M., Mussap M., Gallina P. et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 2005; 16 (Suppl. 1): S78-S82.
- Färbom P., Wahlstrand B., Almgren P. et al. Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the Nordic diltiazem study. Hypertension. 2008; 52(1): 115-122.
- Furtner M., Kiechl S., Mair A. et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur. Heart. J. 2005; 26: 279-287.
- Böhm M., Reil J.C., Danchin N. et al. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J. Hypertens. 2008; 26(1): 18-25.
- Boersma C., Postma M.J., Visser S.T. et al., PREVEND Study Group. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Br. J. Clin. Pharmacol. 2008; 65(5): 723-732.
- Eguchi K., Matsui Y., Shibasaki S. et al. Changes in self-monitored pulse pressure correlate with improvements in B-type natriuretic peptide and urinary albumin in treated hypertensive patients. Am. J. Hypertens. 2007; 20(12): 1268-1275.
- Ibsen H., Olsen M.H., Wachtell K. et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J. Nephrol. 2008; 21(4): 566-569.
- Cottone S., Mule G., Nardi E. et al. Microalbuminuria and early endothelial activation in essential hypertension. J. Hum. Hypertens. 2006;.36: 115-118.
- Dell'Omo G., Penno G., Giorgi D. et al. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am. J. Kidney Dis. 2002; 40(1): 1-8.
- Delles C., Schmieder R.E. Renal endothelial effects of antihypertensive therapy. Curr. Opin. Nephrol. Hypertens. 2004; 13: 489-493.
- Parving H-H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870-878.
- Opie L.H., Parving H.-H. Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643-645.
- Persson F., Rossing P., Hovind P. et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes. 2006; 55(12): 3550-3555.
- Llewelyn D.E., Garcia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics. J. Renin Angiotensin Aldosterone Syst. 2004; 5(3): 141-145.
- Rossing K., Christensen P.K., Andersen S. et al. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care. 2003; 26(3): 569-574.
- Persson F., Rossing P., Hovind P. et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand. J. Clin. Lab. Invest. 2008; 68(8): 731-738.
- Asselbergs F.W., Diercks G.F.H., Hillege H.L. et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816.
- Hillege H.L., Janssen W.M., Bak A.A. et al. Microalbuminuria is common, also in a non-diabetic, non-hypertensive population, and an independent indicator of a cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. 2001; 249: 519-526.
- Mogensen.C.E. Twelve shifting paradigms in diabetic renal disease and hypertension. Diabetes Res. Clin. Pract. 2008; 82 (Suppl. 1): S2-S9.
Дополнительные файлы
![](/img/style/loading.gif)